Tamoxifen (Soltamox) vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
No aligned efficacy figure on record for this race.
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tamoxifen (Soltamox) | Vepdegestrant |
|---|---|---|
| PFS, median | 20.2 vs 15.6vs Endocrine TherapyNCT006019002 other results
| 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | 47.2 vs 43.9vs Endocrine TherapyNCT006019001 other result
| —Trial running · NCT05909397 |
| ORR | 30%bNCT02668666 | 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | 64%bNCT02668666 | 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Tamoxifen (Soltamox)
- 20.2 vs 15.6vs Endocrine TherapyNCT00601900
2 other results
- 5 NCT03045653
- 9.1 NCT02668666
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Tamoxifen (Soltamox)
- 47.2 vs 43.9vs Endocrine TherapyNCT00601900
1 other result
- 18.8 NCT02913430
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Tamoxifen (Soltamox)
- 30%bNCT02668666
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Tamoxifen (Soltamox)
- 64%bNCT02668666
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Tamoxifen (Soltamox): 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tamoxifen (Soltamox) | Vepdegestrant |
|---|---|---|
| Dropout rate | 0%a NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT01027416 · Phase na · registry result, not featured evidence | 7.8%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results— NCT00036270 · Phase 3 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination — NCT02913430 · Phase 1 · registry result, not featured evidence · combination — NCT01027416 · Phase na · registry result, not featured evidence | —a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 28.7%a NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 0% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0% NCT01027416 · Phase na · registry result, not featured evidence | 4%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 11 more resultshot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination arthralgia 33.3% back pain 33.3% headache 33.3% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination headache 32.1% (placebo 0%) night sweats 32.1% (placebo 0%) irritability 28.6% (placebo 0%) NCT01027416 · Phase na · registry result, not featured evidence | a hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tamoxifen (Soltamox)
show 1 more result
show 2 more results
show 1 more result
show 1 more result
+ 6 further endpoints in the CSV export.
Vepdegestrant
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
Reported efficacy
Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)
Result source: NCT00066690
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Tamoxifen (Soltamox): 5 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tamoxifen (Soltamox) | Vepdegestrant |
|---|---|---|
| PFS time to event · months | 20.2 vs 15.6 Endocrine Therapy monthsa,b,c NCT00601900 · Phase 3 · registry result, not featured evidence · combination | 3.7 vs 3.6 Fulvestrant monthsd,a,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose5 vs 2.1 Fulvestrant months NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 29.6%E+OFSe NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results26.7%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 0% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 10%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 9.1%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 3.2%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 20%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 0% NCT01614210 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 17.6% NCT00499083 · Phase 2 · registry result, not featured evidence | 7.8%e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 13.2%E+OFSe NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results6.8%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination — NCT00601900 · Phase 3 · registry result, not featured evidence · combination —TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence —TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence —Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence — NCT01614210 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT00499083 · Phase 2 · registry result, not featured evidence | —e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 37.5%E+OFSe NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results37.2%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 28.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 20.7%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 22.9%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence 0%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 0%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 1.9% NCT01614210 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence | 4%e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e hot flashes/flushes 81.9% pain - joint 77.7% fatigue (asthenia, lethargy, malaise) 59% NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 13 more resultshot flashes/flushes 80% pain - joint 69.5% sweating (diaphoresis) 61.7% NCT00066690 · Phase 3 · registry result, not featured evidence · combination arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination other/minor (not categorized) 24% bone pain 20.9% fatigue 15.6% NCT00295646 · Phase 3 · registry result, not featured evidence bone pain 29.3% other/minor (not categorized) 24.9% fatigue 18.2% NCT00295646 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination hot flashes 36.5% nausea 21.2% fatigue 9.6% NCT01614210 · Phase 2 · registry result, not featured evidence anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination bone pain 33.3% hypokalemia 33.3% mucositis oral 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence | e hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: eligible sex differs (FEMALE versus ALL).
- bTreatment context differs: combination versus monotherapy.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tamoxifen (Soltamox)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 3 more results
show 3 more results
show 1 more result
+ 9 further endpoints in the CSV export.
Vepdegestrant
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tamoxifen (Soltamox)'s landscape · Vepdegestrant's landscape